Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines

被引：35

作者：

Khurana, Surender ^{[1
]}

Larkin, Christopher ^{[2
]}

Verma, Swati ^{[1
]}

Joshi, Manju B. ^{[2
]}

Fontana, Juan ^{[3
]}

Steven, Alasdair C. ^{[3
]}

King, Lisa R. ^{[1
]}

Manischewitz, Jody ^{[1
]}

McCormick, William ^{[2
]}

Gupta, Rajesh K. ^{[2
]}

Golding, Hana ^{[1
]}

机构：

[1] US FDA, Div Viral Prod, CBER, Bethesda, MD 20892 USA

[2] US FDA, Div Prod Qual, CBER, Bethesda, MD 20892 USA

[3] NIAMSD, Struct Biol Res Lab, NIH, Bethesda, MD 20892 USA

来源：

VACCINE | 2011年 / 29卷 / 34期

基金：

美国国家卫生研究院;

关键词：

Pandemic influenza; Vaccine potency; Single-radial immunodiffusion assay; H5N1; H1N1; Vaccine; UNIVERSAL ANTIBODIES; VIRUS PROTEINS; HEMAGGLUTININ; QUANTIFICATION; SUBTYPES; ANTIGEN;

D O I：

10.1016/j.vaccine.2011.06.014

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Vaccine production and initiation of mass vaccination is a key factor in rapid response to new influenza pandemic. During the 2009-2010 H1N1 pandemic, several bottlenecks were identified, including the delayed availability of vaccine potency reagents. Currently, antisera for the single-radial immunodiffusion (SRID) potency assay are generated in sheep immunized repeatedly with HA released and purified after bromelain-treatment of influenza virus grown in eggs. This approach was a major bottleneck for pandemic H1N1 (H1N1pdm09) potency reagent development in 2009. Alternative approaches are needed to make HA immunogens for generation of SRID reagents in the shortest possible time. In this study, we found that properly folded recombinant HA1 globular domain (rHA1) from several type A viruses including H1N1pdm09 and two H5N1 viruses could be produced efficiently using a bacterial expression system and subsequent purification. The rHA1 proteins were shown to form functional oligomers of trimers, similar to virus derived HA, and elicited high titer of neutralizing antibodies in rabbits and sheep. Importantly, the immune sera formed precipitation rings with reference antigens in the SRID assay in a dose-dependent manner. The HA contents in multiple H1N1 vaccine products from different manufacturers (and in several lots) as determined with the rHA1-generated sheep sera were similar to the values obtained with a traditionally generated sheep serum from NIBSC. We conclude that bacterially expressed recombinant HA1 proteins can be produced rapidly and used to generate SRID potency reagents shortly after new influenza strains with pandemic potential are identified. Published by Elsevier Ltd.

引用

页码：5657 / 5665

页数：9

共 30 条

[1] Lessons from pandemic influenza A(H1N1): The research-based vaccine industry's perspective [J].

Abelin, Atika ;

Colegate, Tony ;

Gardner, Stephen ;

Hehme, Norbert ;

Palache, Abraham .

VACCINE, 2011, 29 (06) :1135-1138

[2] CRYSTALLINE ANTIGEN FROM INFLUENZA-VIRUS ENVELOPE [J].

BRAND, CM ;

SKEHEL, JJ .

NATURE-NEW BIOLOGY, 1972, 238 (83) :145-&

[3] Universal antibodies and their applications to the quantitative determination of virtually all subtypes of the influenza A viral hemagglutinins [J].

Chun, Stella ;

Li, Changgui ;

Van Domselaar, Gary ;

Wang, Junzhi ;

Farnsworth, Aaron ;

Cui, Xiaoyu ;

Rode, Harold ;

Cyr, Terry D. ;

He, Runtao ;

Li, Xuguang .

VACCINE, 2008, 26 (48) :6068-6076

[4] INFLUENZA VIRUS PROTEINS .1. ANALYSIS OF POLYPEPTIDES OF VIRION AND IDENTIFICATION OF SPIKE GLYCOPROTEINS [J].

COMPANS, RW ;

KLENK, HD ;

CALIGUIRI, LA ;

CHOPPIN, PW .

VIROLOGY, 1970, 42 (04) :880-+

[5] Selective and quantitative detection of influenza virus proteins in commercial vaccines using two-dimensional high-performance liquid chromatography and fluorescence detection [J].

Garcia-Canas, Virginia ;

Lorbetskie, Barry ;

Bertrand, Diane ;

Cyr, Terry D. ;

Girard, Michel .

ANALYTICAL CHEMISTRY, 2007, 79 (08) :3164-3172

[6] The 2009 H1N1 influenza outbreak in its historical context [J].

Gatherer, Derek .

JOURNAL OF CLINICAL VIROLOGY, 2009, 45 (03) :174-178

[7] The annual production cycle for influenza vaccine [J].

Gerdil, C .

VACCINE, 2003, 21 (16) :1776-1779

[8] Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus [J].

Hashem, Anwar M. ;

Van Domselaar, Gary ;

Li, Changgui ;

Wang, Junzhi ;

She, Yi-Min ;

Cyr, Terry D. ;

Sui, Jianhua ;

He, Runtao ;

Marasco, Wayne A. ;

Li, Xuguang .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 403 (02) :247-251

[9] Bsoft: Image processing and molecular modeling for electron microscopy [J].

Heymann, J. Bernard ;

Belnap, David M. .

JOURNAL OF STRUCTURAL BIOLOGY, 2007, 157 (01) :3-18

[10] HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines [J].

Kapteyn, J. C. ;

Porre, A. M. ;

de Rond, E. J. R. ;

Hessels, W. B. ;

Tijms, M. A. ;

Kessen, H. ;

Slotboom, A. M. E. ;

Oerlemans, M. A. ;

Smit, D. ;

van der Linden, J. ;

Schoen, P. ;

Thus, J. L. G. .

VACCINE, 2009, 27 (09) :1468-1477

← 1 2 3 →